Drug Profile
VX 152
Alternative Names: VX-152Latest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Ion channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 11 Oct 2021 Discontinued - Phase-I for Cystic fibrosis (Monotherapy, In volunteers) in USA (PO) before October 2021 (Vertex Pharmaceuticals pipeline, October 2021)
- 11 Oct 2021 Discontinued - Phase-II for Cystic fibrosis (Combination therapy) in USA (PO) before October 2021 (Vertex Pharmaceuticals pipeline, October 2021)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Cystic-fibrosis(Monotherapy, In volunteers) in USA (PO)